PeptideStack
5.2kquestions
20kanswers
220users

How do I reconcile 95.2% from Janoshik with 99.4% from the supplier?

Asked 18 Mar 2025Modified 13 months agoViewed 9.9k times
20

What I have: 95.2% · Janoshik · 99.4%.

I have a result I cannot explain, and I would rather diagnose it than guess.

I have checked the obvious explanations and eliminated the two easiest ones.

What would you check first, and what would you conclude from each outcome?

purity
purity

Purity as chromatographic area per cent - the fraction of detected material that is your target peak. It says nothing about how much material is…

788 questions
batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

865 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

749 questions
shareeditfollowflag
CI
askedcake_intact18k2818 Mar 2025

5 Answers

Accepted answer first, then by votes
39

Accepted answer

Mechanically, purity is a method-dependent figure, and that is not a limitation of the measurement, it is a property of what the measurement actually answers.

Gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.

What each test answers

TestAnswersDoes NOT answer
RP-HPLC, area %What fraction of detected material is the targetHow much target is present
Quantified contentMilligrams of peptide per vialWhat the impurities are
ESI-MS identityWhether the molecular weight matchesPurity, or isomeric substitution
Peptide mappingSequence, localised to a fragmentQuantity
Karl FischerWater content of the solidSolvent content
LAL endotoxinPyrogen load in EU/mgSterility
Sterility testGrowth in defined media over 14 daysEndotoxin, or bioburden count

On the detail: detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.

Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.

Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.

If you are ranking vendors, specify a method and have all samples tested at the same place.

shareimprove this answerflag
ZM
answered · acceptedzainab_mustafa16k178 Apr 2025
8Related: the same reasoning applies to the counter-ion question. – Dr_Priya_Raghunathan 34 days ago
add a comment
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
41

Stated carefully, understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.

Column pore size affects mass transfer — a 100 Angstrom packing on a 5 kDa peptide restricts diffusion, broadening the peak and potentially hiding small impurities in the shoulders.

Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
ED
answerede_dziedzic87k24814 Jul 2025
28

Worth being precise here: the method matters more than the vial, which is why specifying a method buys you far more than changing suppliers does.

Buffer versus acid in the mobile phase changes the ionisation state of basic and acidic residues, shifting retention and selectivity — same vial, potentially different separation.

The fraction of your main peak that is actually your target versus isomers, fragments or related sequences is invisible without complementary identity testing.

The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.

shareimprove this answerflag
DH
answeredDr_Jonas_Halvorsen41k383 Jul 2025
18

To be exact about it, read the chromatogram before you read the number, because the number without the trace is not a measurement, it is a claim.

Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.

The Arrhenius relationship for peptide degradation is the basis of accelerated stability testing and also governs how quickly methods drift with temperature.

If you are ranking vendors, specify a method and have all samples tested at the same place.

edited 20 Apr 2025 by u100_marks — fixed an arithmetic slip in the third paragraph

shareimprove this answerflag
UM
answeredu100_marks38k3827 Mar 2025
I have seen exactly this failure mode twice and both times it was the diluent. – micron22 6 months ago
8The distinction between purity and content cannot be repeated often enough here. – greta_holzmann 5 months ago
add a comment
16

Concretely, reporting threshold is convention and not chemistry, which is why two certificates with different thresholds disagree by a tenth of a point or more.

Integration of the shoulder — whether you use perpendicular drop or tangent skim — determines what area gets assigned to the main peak versus the impurity table.

Compare purity within a single laboratory on the same method, never across laboratories.

shareimprove this answerflag
RS
answeredruaidhri_o_shea51k3831 May 2025
4Adding for future readers: the certificate should carry the lot number, not just a batch code. – Dr_Colm_Fitzhenry 4 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.